Skip to main content
SpringerLink
Log in

The influence of long-term anticonvulsant therapy with diphenylhydantoin and carbamazepine on serum gamma-glutamyltransferase, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase

  • Published:
European archives of psychiatry and neurological sciences Aims and scope Submit manuscript

Summary

In 110 patients receiving long-term anticonvulsant monotherapy with diphenylhydantoin (DPH) and carbamazepine (CBZ) the serum activities of gamma-glutamyltransferase (γ-GT), aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase (AP) were examined retrospectively. Elevated serum levels of γ-GT and AP were seen in 91% and 39% of patients receiving DPH therapy compared to 64% and 14% of those receiving CBZ treatment. With all enzymes evaluated increases were more frequent and higher with DPH treatment than with CBZ. Frequency and extent of increased activity of γ-GT were highly related to daily dosage in both preparations. The proportion of pathological enzyme levels was associated with age in DPH and CBZ therapies but not found to be significant. Sex differences in the frequency of increased enzyme activities could not be demonstrated. The results are discussed in the context of induction of the cytochrome P-450 system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aiges HW, Daum F, Olson M, Kahn E, Teichberg S (1980) The effects of phenobarbital and diphenylhydantoin on liver function and morphology. J Pediatr 97:22–26

    Google Scholar 

  2. Bertilsson L, Ekbom K, Sjoequist F, Tomson T (1985) The clinical pharmacology of carbamazepine — a comparison with phenytoin. Laekartidningen 82:1355–1360

    Google Scholar 

  3. Callaghan N, O'Callaghan M, Duggan B, Feely M (1978) Carbamazepine as a single drug in the treatment of epilepsy. J Neurol Neurosurg Psychiatry 41:907–912

    Google Scholar 

  4. Camfield C, Camfield F, Smith E, John AR (1986) Asymptomatic children with epilepsy: Little benefit from screening for anticonvulsant-induced liver, blood or renal damage. Neurology 36:838–841

    Google Scholar 

  5. Deisenhammer E, Schwarzbach H, Sommer R (1982) Erhöhung der Gamma-GT bei antikonvulsiver Therapie. Wien Klin Wochenschr 94:584–585

    Google Scholar 

  6. Farrell GC (1986) The hepatic side-effects of drugs. Med J Aust 145:600–604

    Google Scholar 

  7. Farrell GC (1986) Hepatic drug reactions: how unpredictable are they? J Gastroenterol Hepatol 1:267–271

    Google Scholar 

  8. Fichsel H (1981) Veränderungen der Leberenzyme unter antikonvulsiver Mono- und Kombinationsbehandlung epileptischer Kinder. In: Remschmidt H, Rentz R, Jungmann J (Hrsg) Epilepsie 1980. Thieme, Stuttgart New York, pp 148–151

    Google Scholar 

  9. Fröscher W, Eichelbaum M, Hildenbrand G, Hildenbrand K, Penin H (1982) Prospektive Untersuchungen zur Epilepsietherapie mit Carbamazepin. Fortschr Neurol Psychiatr 50:396–408

    Google Scholar 

  10. Giroud M, D'Athis P, Guard O, Soichot P, Dumas T (1985) Evaluation of gamma-GT involvement under a long-term treatment with anticonvulsants. Pathol Biol 33:810–818

    Google Scholar 

  11. Giroud M, D'Athis P, Guard O, Soichot P, Dumas R (1986) Evaluation of changes in gamma-GT under longterm anticonvulsant treatment. Semin Hop Paris 62:1795–1801

    Google Scholar 

  12. Gram L, Bentson KD (1983) Hepatic toxity of antiepileptic drugs: A review. Acta Neurol Scand 68 Suppl 97:81–90

    Google Scholar 

  13. Gugler R (1985) Hepatische Arzneimittelreaktionen. Fortschr Med 103:953–955

    Google Scholar 

  14. Heiperts R, Eickhoff K, Poser W (1978) Anticonvulsant therapy and serum-γ-glutamyltransferase. Klin Wochenschr 56:921–928

    Google Scholar 

  15. Hopen G, Nesthaus I, Laerum OD (1981) Fatal carbamazepine hepatitis. Acta Med Scand 210:333–335

    Google Scholar 

  16. Jeavons PM (1983) Hepatotoxicity of antiepileptic drugs. In: Oxley J, Janz D, Meinardi H (eds) Chronic toxicity of intiepileptic drugs. Raven Press, New York, pp 1–45

    Google Scholar 

  17. Jeavons PM (1983) Hepatotoxicity of antiepileptic drugs. In: Parsonage M, Graig AG, Grant RHE, Ward AA (eds) Advances in epileptology. The XIVth Epilepsy International Symposium. Raven Press, New York, pp 263–272

    Google Scholar 

  18. Kruse R (1975) Osteopathien, Kalzium- und Vitamin-DStoffwechselstörungen unter antiepileptischer Langzeittherapie. Bibl Psychiatr 151:114–143

    Google Scholar 

  19. Kutt H, Solomon GR (1980) Antiepileptic drugs: Phenytoin: relevant side effects. In: Glaser GH, Penry JK, Woodbury DM (eds) Antiepileptic drugs: mechanism of action. Raven Press, New York, pp 435–445

    Google Scholar 

  20. Levy M, Goodman MW, Van Dyne B, Summer HW (1981) Granulomatous hepatitis secondary to carbamazepine. Ann Intern Med 95:64–65

    Google Scholar 

  21. Luoma PV, Sotaniemi EA, Pelkonen RO, Pirttiaho HI (1985) Serum low-density lipoprotein and high-density lipoprotein cholesterol, and liver size in subjects on drugs inducing hepatic microsomal enzymes. Eur J Clin Pharmacol 28:615–618

    Google Scholar 

  22. Martin W, Rickers J (1972) Cholestatische Hepatose nach Diphenylhydantoin. Wien Klin Wochenschr 84:41–45

    Google Scholar 

  23. Meyer-Wahl JG, Häusermann B, Lewin L, Meyer-Wahl I (1984) Leberwerte bei antikonvulsiver Behandlung. In: Hallen O, Meyer-Wahl JG, Braun J (Hrsg) Epilepsie 82. Spät- und Residualepilepsien, Nebenwirkungen von Antikonvulsiva. Einhorn-Presse, Reinbeck, pp 263–275

    Google Scholar 

  24. Mullick FG, Ishak KG (1980) Hepatic injury associated with diphenylhydantoin therapy. Am J Clin Pathol 74:442–452

    Google Scholar 

  25. Nordin G, Hemdal I, Olsson JE, Rolny P (1983) Liver damage and antiepileptic drugs. 15th Epilepsy International Symposium. Washington D. C., Sept. 26–30, Abstr. p 470

  26. Offermann G, Pinto V, Kruse R (1979) Antiepileptic drugs and vitamin D supplementation. Epilepsia 20:3–15

    Google Scholar 

  27. O'Hara JA, Duggan B, O'Driscoll D, Callaghan N (1980) Biochemical evidence for osteomalacia with carbamazepine therapy. Acta Neurol Scand 62:282–286

    Google Scholar 

  28. Parker WA, Shearer CA (1979) Phenytoin hepatotoxicity: A case report and review. Neurology 29:175–178

    Google Scholar 

  29. Pirttiano HI, Sotaniemi EA, Pelkonen RO, Pitkänen U (1982) Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants. Eur J Clin Pharmacol 22:441–445

    Google Scholar 

  30. Reynolds EH, Shorvan SD, Galbraith AW, Chadwick D, Dellaportas CI, Vydelingum L (1981) Phenytoin monotherapy for epilepsy: A long-term prospective study, assisted by serum level monitoring, in previously untreated patients. Epilepsia 22:475–488

    Google Scholar 

  31. Sano J, Kawada H, Yamaguchi N, Kawakita M, Kobayashi K (1981) Effects of phenytoin on serum gamma-glutamyltranspeptidase activity. Epilepsia 22:331–338

    Google Scholar 

  32. Schmidt D (1983) dePharmakotherapie von Epilepsien — Aktuelle Fragen und Kontroversen. Fortschr Neurol 51:363–386

    Google Scholar 

  33. Shorvon SD, Galbraith AW, Laundy M, Vydelingum L, Reynolds EH (1980) Monotherapy for epilepsy. In: Johannessen SI, Morselli PL, Pippenger CE, Richens A, Schmidt D, Meinardi H (eds) Antiepileptic therapy: advances in drug monitoring. Raven Press, New York, pp 213–220

    Google Scholar 

  34. Strandjord RA, Johannessen SI (1980) Carbamazepine as the only drug in patients with epilepsy: Serum levels and clinical effects. In: Johannessen SI, Morselli PL, Ippenger CE, Richens A, Schmidt D, Meinardi H (eds) Antiepileptic therapy: advances in drug monitoring. Raven Press, New York, pp 229–233

    Google Scholar 

  35. Teschke R (1983) deBereits alkoholbedingte Fettleber behandeln? Klinikarzt 12:610–616

    Google Scholar 

  36. Turner P, Pearson RM (1987) Adverse drug reactions and poisoning. In: Kumar PV, Clark ML (eds) Clinical medicine. Bailliere Tindall, London, pp 650–672

    Google Scholar 

  37. Zucker P, Daum F, Cohen MI (1977) Fatal carbamazepine hepatitis. J Pediatr 91:667–668

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Krankenhäuser des Märkischen Kreises, Akademisches Lehrkrankenhaus der Universität Bonn, Abteilung Neurologie, Postfach 2020, D-5880, Germany

    Heinz Große Aldenhövel

Authors
  1. Heinz Große Aldenhövel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aldenhövel, H.G. The influence of long-term anticonvulsant therapy with diphenylhydantoin and carbamazepine on serum gamma-glutamyltransferase, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase. Eur Arch Psychiatr Neurol Sci 237, 312–316 (1988). https://doi.org/10.1007/BF00450552

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00450552

Key words

Search

Navigation